433 results on '"Berger PB"'
Search Results
2. HIGHER PTCA MORTALITY IN WOMEN RELATED MORE TO DISEASE SEVERITY THAN GENDER
3. The relative safety and efficacy of clopidogrel in women and men: Meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMA
4. Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO-trial.
5. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial.
6. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
7. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
8. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
9. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry.
10. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions appropriateness of including bleeding as a component of a quadruple end point.
11. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
12. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry.
13. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial.
14. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.
15. Independent association between plasma leptin and C-reactive protein in healthy humans.
16. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease.
17. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
18. Management of patients undergoing percutaneous coronary revascularization.
19. Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS)
20. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective.
21. The changing face of coronary interventional practice. The Mayo Clinic experience.
22. The Glycoprotein IIb/IIIa Inhibitor Wars An Update.
23. Optimal duration of clopidogrel use after implantation of drug-eluting stents--still in doubt.
24. Bleeding is bad... isn't it?
25. Clopidogrel and percutaneous coronary interventions.
26. Editorial Defense Challenged
27. Cardiogenic shock -- beyond the large infarction.
28. A glucose-insulin-potassium infusion did not reduce, mortality, cardiac arrest, or cardiogenic shock after acute MI.
29. Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI.
30. Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
31. Bivalirudin reduced major bleeding and adverse events in patients with STEMI having PCI.
32. Review: reduction in resting heart rate after taking beta-blockers or calcium-channel blockers reduce mortality and morbidity after MI.
33. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
34. Review: early statin therapy does not reduce the composite endpoint of death, MI, or stroke in acute coronary syndromes.
35. Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction.
36. Percutaneous transluminal coronary angioplasty improved long-term angina status more than medical therapy in coronary artery disease.
37. Perindopril reduced cardiac events in stable coronary artery disease.
38. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
39. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
40. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.
41. Six-Month Follow-Up of Patients With In-Hospital Thrombocytopenia During Heparin-Based Anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] Registry)
42. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial)
43. Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery disease.
44. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)
45. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
46. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
47. Percutaneous coronary intervention for ST-segment and non-ST-segment elevation myocardial infarction at hospitals with and without on-site cardiac surgical capability.
48. Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study)
49. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
50. Clinical safety of magnetic resonance imaging early after coronary artery stent placement.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.